Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. [electronic resource]
Producer: 20081006Description: 488-95 p. digitalISSN:- 1555-8576
- Adult
- Aged
- Bacterial Outer Membrane Proteins -- immunology
- Cancer Vaccines -- immunology
- Eye Neoplasms -- drug therapy
- Female
- G(M3) Ganglioside -- analogs & derivatives
- Humans
- Immunoglobulin A -- blood
- Immunoglobulin G -- blood
- Immunoglobulin M -- blood
- Liposomes
- Male
- Mannitol -- administration & dosage
- Melanoma -- drug therapy
- Middle Aged
- Neisseria meningitidis -- immunology
- Oleic Acids -- administration & dosage
- Skin Diseases -- drug therapy
- Survival Analysis
- Treatment Outcome
- Vaccination
- Vitiligo -- immunology
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.